Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males
Launched by ACRUX DDS PTY LTD · Sep 5, 2006
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Hypogonadal males between 18-70 years old with qualifying general medical health
- Exclusion Criteria:
- • Disqualifying concurrent conditions or allergy/sensitivity to testosterone replacement therapy
About Acrux Dds Pty Ltd
Acrux DDS Pty Ltd is an innovative pharmaceutical company specializing in the development of advanced drug delivery systems. With a strong focus on improving patient outcomes, Acrux leverages its proprietary technology to create enhanced formulations for a range of therapeutic areas, including hormonal therapies and vaccines. The company is committed to rigorous clinical research and development processes, ensuring the safety and efficacy of its products. Acrux's vision is to transform healthcare through cutting-edge solutions that optimize medication adherence and effectiveness.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Shreveport, Louisiana, United States
Torrance, California, United States
New Britain, Connecticut, United States
La Mesa, California, United States
Shreveport, Louisiana, United States
Ocala, Florida, United States
Birmingham, Alabama, United States
Patients applied
Trial Officials
Tina Soulis, PhD
Study Director
Acrux Ltd
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials